Literature DB >> 3921191

6-OHDA lesions of the ventral tegmental area block morphine-induced but not amphetamine-induced facilitation of self-stimulation.

T H Hand, K B Franklin.   

Abstract

The biphasic effect of morphine on intracranial self-stimulation (ICSS) (suppression followed by facilitation) was examined in rats following injections of 6-OHDA or vehicle into the ventral tegmental area (VTA). During 7 days of chronic administration of morphine, sham-lesioned animals gradually developed tolerance to the rate-reducing effects of the drug and a concurrent sensitization to its rate-enhancing effects (measured 1 and 3 h post-injection, respectively). VTA lesioned rats showed neither tolerance to the rate suppression nor any facilitation of ICSS throughout testing. Amphetamine's facilitation of ICSS remained intact in all subjects. The lesion was restricted to the VTA cell bodies but produced a significant depletion of dopamine (DA) in both the nucleus accumbens and in the striatum. Morphine facilitation of ICSS is suggested to be dependent on an indirect opiate receptor-VTA DA cell interaction. It is also proposed that amphetamine facilitation of ICSS is a 'mass action' effect involving the full DA terminal area of the forebrain rather than a subregion of that area.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3921191     DOI: 10.1016/0006-8993(85)91034-0

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  10 in total

Review 1.  Striatal action-learning based on dopamine concentration.

Authors:  Genela Morris; Robert Schmidt; Hagai Bergman
Journal:  Exp Brain Res       Date:  2009-11-11       Impact factor: 1.972

2.  The CCKB antagonist PD-134,308 facilitates rewarding effects of endogenous enkephalins but does not induce place preference in rats.

Authors:  O Valverde; M C Fournie-Zaluski; B P Roques; R Maldonado
Journal:  Psychopharmacology (Berl)       Date:  1996-01       Impact factor: 4.530

3.  Blockade of dopamine receptors reverses the behavioral effects of endogenous enkephalins in the Nucleus caudatus but not in the Nucleus accumbens: differential involvement of delta and mu opioid receptors.

Authors:  V Daugé; P Rossignol; B P Roques
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

4.  Associative factors in the effects of morphine on self-stimulation.

Authors:  T H Hand; K B Franklin
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

5.  Brain stimulation and morphine reward deficits in dopamine D2 receptor-deficient mice.

Authors:  G I Elmer; J O Pieper; J Levy; M Rubinstein; M J Low; D K Grandy; R A Wise
Journal:  Psychopharmacology (Berl)       Date:  2005-09-29       Impact factor: 4.530

6.  Acute and chronic methylphenidate administration in intact and VTA-specific and nonspecific lesioned rats.

Authors:  Stephanie A Ihezie; Ming M Thomas; Nachum Dafny
Journal:  J Neural Transm (Vienna)       Date:  2019-01-08       Impact factor: 3.575

7.  Differential mechanisms in the acquisition and expression of heroin-induced place preference.

Authors:  T H Hand; L Stinus; M Le Moal
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

8.  Chronic dopamine antagonism facilitates opiate-induced feeding.

Authors:  F J Vaccarino; J S Mogil; L Stinus
Journal:  J Psychiatry Neurosci       Date:  1995-05       Impact factor: 6.186

9.  Heparan sulfate: Resilience factor and therapeutic target for cocaine abuse.

Authors:  Jihuan Chen; Tomoya Kawamura; Manveen K Sethi; Joseph Zaia; Vez Repunte-Canonigo; Pietro Paolo Sanna
Journal:  Sci Rep       Date:  2017-10-24       Impact factor: 4.379

10.  Effects of the selective dopamine D3 receptor antagonist PG01037 on morphine-induced hyperactivity and antinociception in mice.

Authors:  Christian A Botz-Zapp; Stephanie L Foster; Desta M Pulley; Briana Hempel; Guo-Hua Bi; Zheng-Xiong Xi; Amy Hauck Newman; David Weinshenker; Daniel F Manvich
Journal:  Behav Brain Res       Date:  2021-08-02       Impact factor: 3.352

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.